Newly formed company founded by prominent Yale professors will advance development of novel RNA therapies and vaccine adjuvants for local…
EBT-101 is an in vivo CRISPR-based therapeutic designed to remove HIV proviral DNA from affected cell reservoirs First-in-human study will…
– Transaction values Apollomics at pre-money equity value of $899 million– Apollomics is a late-stage clinical biopharmaceutical company developing innovative…
LUNA Phase 2 Study in Wet AMD - Study Design Objective: The LUNA trial is a multicenter, double-masked, randomized, parallel-group…
BETHLEHEM, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home…
MEMPHIS, Tenn., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Black mothers die in hospitals at nearly four times the rate of White mothers…
SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging…
Marks first randomized Phase 2/3 trial of CRISPR-enhanced bacteriophage precision medicineRESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) --…
ABILITY Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with Merck’s KEYTRUDA® (pembrolizumab) for treatment of…
Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, September 13, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage…